Three patients were diagnosed at our facility with therapy-related acute myeloid leukemia (t-
AML) but had differing etiologies. Patient A was a 30-year-old male with a history of acute …

Patients with primary cancer receiving chemotherapy and/or radiotherapy may develop
therapy‑related acute leukemia (t‑AL). Therapy‑related acute myeloid leukemia (t‑AML) …

Purpose To learn whether an antecedent hematologic disorder (AHD) is associated with
additional risk in patients with therapy-related acute myeloid leukemia (t-AML). Patients and …

Therapy-related acute lymphoblastic leukemia (t-ALL) is a rare potential complication of
chemotherapy. We describe the case of a 47-year-old male patient who was originally …

Therapy-related acute myeloid leukemia (tAML) and acute myeloid leukemia (AML) with
myelodysplasia-related changes represent 2 distinct subcategories of the 2016 revision of …

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous group of myeloid neo‐-
plasms occurring as an overwhelming complication in patients receiving previous cytotoxic …

Background: Therapy-related acute myeloid leukemia (AML) is a well-described entity and
known to carry a worse prognosis, compared to de novo AML. In the current study, we …

Context t-AL arises after exposure to cytotoxic chemotherapy and/or radiation therapy and is
associated with poor prognosis. t-AL tends to have adverse cytogenetics, unlike acute …

Therapy-related acute myelogenous leukemia (t-AML) is a recognizable subclass of acute
myelogenous leukemia (AML). Features of the syndrome include a preleukemic phase …

Therapy-related acute myeloid leukemia (t-AML) is a rare and almost always fatal late side
effect of antineoplastic treatment involving chemotherapy, radiotherapy or the two combined …